U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C19H32N2.3C4H4O4
Molecular Weight 925.158
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 3
Charge 0

SHOW SMILES / InChI
Structure of TEDISAMIL SESQUIFUMARATE

SMILES

OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.C(C1CC1)N2CC3CN(CC4CC4)CC(C2)C35CCCC5.C(C6CC6)N7CC8CN(CC9CC9)CC(C7)C8%10CCCC%10

InChI

InChIKey=AZPYPAVFNGFTGB-VQYXCCSOSA-N
InChI=1S/2C19H32N2.3C4H4O4/c2*1-2-8-19(7-1)17-11-20(9-15-3-4-15)12-18(19)14-21(13-17)10-16-5-6-16;3*5-3(6)1-2-4(7)8/h2*15-18H,1-14H2;3*1-2H,(H,5,6)(H,7,8)/b;;3*2-1+

HIDE SMILES / InChI

Molecular Formula C19H32N2
Molecular Weight 288.4708
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Tedisamil is an antiarrhythmic with additional anti-ischaemic properties, which acts via potassium channel blockade. This drug can be categorised as a class III antiarrhythmic agent due to its effects of action potential and QT interval prolongation in these patients. Although tedisamil has been shown to be an effective anti-ischaemic agent, with Phase III trials for angina pectoris now completed, the company are now pursuing the use of tedisamil for the treatment of atrial fibrillation, for which tedisamil is still in Phase II/III clinical trials. The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted not to recommend approval for Solvay Pharmaceuticals’ investigational anti-arrhythmic drug Pulzium (Tedisamil) and asked the company to give the FDA more information.

Approval Year

PubMed

PubMed

TitleDatePubMed
Genomic organization, chromosomal localization, tissue distribution, and biophysical characterization of a novel mammalian Shaker-related voltage-gated potassium channel, Kv1.7.
1998 Mar 6
Dispersion of cell-to-cell uncoupling precedes low K+-induced ventricular fibrillation.
2001
Transgenic mice overexpressing human KvLQT1 dominant-negative isoform. Part II: Pharmacological profile.
2001 May
Newer antiarrhythmic drugs.
2001 May-Jun
Modulation of intracellular Ca(2+) concentration by tedisamil, a class III antiarrhythmic agent, in isolated heart preparation.
2003 Aug 22
Tedisamil in coronary disease: additional benefits in the therapy of atrial fibrillation?
2003 Jun
Atrial fibrillation: emerging possibilities for drug treatment: an overview of current opportunities and recent developments.
2003 Jun
Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation.
2004
Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
2008
Update on atrial fibrillation: part II.
2008 Mar
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?
2008 Sep 22
Atrial fibrillation: from ion channels to bedside treatment options.
2009 Nov-Dec

Sample Use Guides

The recommended dose is 0.32 mg/kg
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Fri Dec 16 19:09:23 UTC 2022
Edited
by admin
on Fri Dec 16 19:09:23 UTC 2022
Record UNII
Y4HRG433UU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TEDISAMIL SESQUIFUMARATE
DASH   MI   USAN   WHO-DD  
USAN  
Official Name English
KC-8857 SESQUIFUMARATE
Code English
TEDISAMIL SESQUIFUMARATE [USAN]
Common Name English
Tedisamil sesquifumarate [WHO-DD]
Common Name English
PULZIUM
Brand Name English
SPIRO(CYCLOPENTANE-1,9'-(3,7)DIAZABICYCLO(3.3.1)NONANE), 3',7'-BIS(CYCLOPROPYLMETHYL)-, (2E)-2-BUTENEDIOATE (2:3)
Common Name English
TEDISAMIL SESQUIFUMARATE [MI]
Common Name English
BIS(3',7'-BIS(CYCLOPROPYLMETHYL)SPIRO(CYCLOPENTANE-1,9'-(3,7)DIAZABICYCLO(3.3.1)NONANE))DIHYDROGEN TRIS((2E-BUT-2-ENEDIOATE)
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C93038
Created by admin on Fri Dec 16 19:09:23 UTC 2022 , Edited by admin on Fri Dec 16 19:09:23 UTC 2022
NCI_THESAURUS C47793
Created by admin on Fri Dec 16 19:09:23 UTC 2022 , Edited by admin on Fri Dec 16 19:09:23 UTC 2022
Code System Code Type Description
ChEMBL
CHEMBL113461
Created by admin on Fri Dec 16 19:09:23 UTC 2022 , Edited by admin on Fri Dec 16 19:09:23 UTC 2022
PRIMARY
CAS
150501-62-5
Created by admin on Fri Dec 16 19:09:23 UTC 2022 , Edited by admin on Fri Dec 16 19:09:23 UTC 2022
PRIMARY
USAN
RR-134
Created by admin on Fri Dec 16 19:09:23 UTC 2022 , Edited by admin on Fri Dec 16 19:09:23 UTC 2022
PRIMARY
NCI_THESAURUS
C73802
Created by admin on Fri Dec 16 19:09:23 UTC 2022 , Edited by admin on Fri Dec 16 19:09:23 UTC 2022
PRIMARY
PUBCHEM
11498917
Created by admin on Fri Dec 16 19:09:23 UTC 2022 , Edited by admin on Fri Dec 16 19:09:23 UTC 2022
PRIMARY
EVMPD
SUB22754
Created by admin on Fri Dec 16 19:09:23 UTC 2022 , Edited by admin on Fri Dec 16 19:09:23 UTC 2022
PRIMARY
CHEBI
134747
Created by admin on Fri Dec 16 19:09:23 UTC 2022 , Edited by admin on Fri Dec 16 19:09:23 UTC 2022
PRIMARY
MERCK INDEX
M10516
Created by admin on Fri Dec 16 19:09:23 UTC 2022 , Edited by admin on Fri Dec 16 19:09:23 UTC 2022
PRIMARY Merck Index
FDA UNII
Y4HRG433UU
Created by admin on Fri Dec 16 19:09:23 UTC 2022 , Edited by admin on Fri Dec 16 19:09:23 UTC 2022
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY